Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
DEXFERRUM (iron dextran) is an injectable iron replacement therapy administered intravenously or intramuscularly to treat iron deficiency anemia. It replenishes depleted iron stores in patients who cannot tolerate or absorb oral iron supplements. The drug binds iron to dextran, allowing systemic delivery and rapid incorporation into hemoglobin.
Approaching loss of exclusivity signals team transition toward lifecycle management and defensive positioning rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Intravaneous Iron(1000 mg Low Molecular Weight Iron Dextran Over 60 Minutes) for Pregnant Women
Working on DEXFERRUM at this lifecycle stage positions you in a defensive, mature-product environment where success centers on market-share protection, payer relationships, and preparation for exclusivity loss. Roles emphasize managed-care negotiation and cost-effectiveness messaging over launch or growth execution.
Worked on DEXFERRUM at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo